Volume 9, Supplement 1 (Nov/Dec 2018)
Volume 9, Supplement 1 (Nov/Dec 2018)
Incidence rates of melanoma continue to climb, and while most patients are diagnosed at an early stage, once metastatic, melanoma remains the most deadly of all the cutaneous malignancies. With the discovery of immune checkpoints and therapies that target the MAPK pathway, patients with metastatic melanoma have new treatment options and renewed hope.
Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes
November 27, 2018
Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma
November 27, 2018
Advertisement
Current Issue
Vol 15
No 6
Sep/Oct 2024
Is it Cellulitis Again? Erythema Concerning for Infection in Children With High-Risk Solid Tumors Who Have a Gastrostomy Tube
Kristen L. Dalton, MSN, RN, CPNP-AC, CPHON, Meredith R. Johnson, MSN, RN, CRNP-AC
September 16, 2024
Carcinoid Heart Disease
Nicole Kuhnly, MS, ACNPC-AG, Jessica Shank Coviello, DNP, APRN, ANP-BC, Catherine A. Kobza, MSN, AGACNP-BC, Et al.
September 16, 2024